Loading
PB
POINT Biopharma Global Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 30 Nov 2022.
POINT Biopharma Global Inc.: what insiders have been doing
POINT Biopharma Global Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). No insider at POINT Biopharma Global Inc. has published a filing in the past twelve months. The most recent one dates from 27 December 2023.
Looking back to 2021, when coverage begins, insiders filed 8 purchases and 2 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
30
Thresholds
n/a
Buy Volume
€2M
8 ops. · all time
Sell Volume
€107M
2 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$195.1M
Net incomeUS$84.6M43.4% margin
Last declaration on 27 December 2023
Declarations30 total
4,268,605 sharesCommon StockSEC:0001104659-23-129767:0
41,872 sharesCommon StockSEC:0001104659-23-129777:0
35,400 sharesCommon StockSEC:0001104659-23-129769:0
3,700 sharesCommon StockSEC:0001104659-23-129770:0
1,710 sharesCommon StockSEC:0001104659-23-129766:0
2,773,045 sharesCommon StockSEC:0001104659-23-129772:0
21,596 sharesCommon StockSEC:0001104659-23-129771:0
2,160 sharesCommon StockSEC:0001104659-23-129775:0
8,974,245 shares@ US$12.45100.0% of flowCommon Stock, $0.0001 par valueSEC:0001193805-23-001635:0
120,000 shares0Common StockSEC:0001104659-23-115375:0
500,000 shares0Common StockSEC:0001104659-23-115374:0
250,000 shares0Common StockSEC:0001104659-23-113897:0
17,936 shares@ US$6.9783.0% of flowCommon StockSEC:0001104659-23-036164:0
2,160 shares@ US$6.64100.0% of flowCommon StockSEC:0001104659-22-123356:0
Canonical exit: 27 Feb 2023 (T+90)
3,660 shares@ US$6.81517.0% of flowCommon StockSEC:0001104659-22-122396:0
Canonical exit: 23 Feb 2023 (T+90)
3,600 shares@ US$6.85100.0% of flowCommon StockSEC:0001104659-22-122395:0
Canonical exit: 21 Feb 2023 (T+90)
3,700 shares@ US$6.66100.0% of flowCommon StockSEC:0001104659-22-122390:0
Canonical exit: 26 Feb 2023 (T+90)
1,710 shares@ US$6.56100.0% of flowCommon StockSEC:0001104659-22-121618:0
Canonical exit: 19 Feb 2023 (T+90)
6,000 shares@ US$6.33100.0% of flowCommon StockSEC:0001104659-22-120875:0
Canonical exit: 16 Feb 2023 (T+90)
27,603 shares@ US$6.00100.0% of flowCommon StockSEC:0001104659-22-120873:0
Canonical exit: 15 Feb 2023 (T+90)
564,204 shares@ US$7.51100.0% of flowCommon StockSEC:0001104659-22-065250:0
35,872 sharesCommon StockSEC:0001104659-22-013375:0
209,100 shares@ US$10.00100.0% of flowCommon StockSEC:0001104659-21-087616:0
Canonical exit: 27 Sept 2021 (T+90)
209,100 shares@ US$10.0019.1% of flowCommon StockSEC:0001104659-21-087618:0
21,523 sharesCommon StockSEC:0001104659-21-087828:0
25 of 30 declarations
About POINT Biopharma Global Inc.
POINT Biopharma Global Inc. was a U.S.-listed biopharmaceutical company formerly traded on the NASDAQ under the ticker PNT before being acquired in late 2023. For international investors, POINT was best understood as a radiopharmaceutical specialist: a company operating at the intersection of oncology, nuclear medicine, and isotope-based drug development. It was founded to build a modern platform for radioligand discovery, clinical development, and manufacturing, with the goal of bringing targeted cancer therapies to market.
The company’s core business centered on an integrated radiopharmaceutical platform. POINT combined internal R&D capabilities with manufacturing infrastructure and access to critical isotopes such as lutetium-177 and actinium-225. Its main pipeline assets were PNT2002, a PSMA-targeted radioligand therapy for prostate cancer, and PNT2003, aimed at neuroendocrine tumors. In addition, POINT was developing earlier-stage next-generation programs to broaden its pipeline beyond the lead assets. This made the company a focused, high-science biotech with a concentrated portfolio and a strong dependence on clinical execution.
Read moreShow less
From a competitive standpoint, POINT operated in a promising but demanding niche. Success in radiopharmaceuticals depends not only on clinical data, but also on supply-chain control, isotope availability, manufacturing quality, regulatory execution, and the ability to scale production. POINT highlighted its in-house manufacturing base in Indianapolis, Indiana, as a strategic advantage for clinical supply and future commercialization. SEC filings also pointed to operational ties in South San Francisco, California, underscoring a footprint across key U.S. biotech hubs. The company also built collaborations designed to support development and commercialization efforts in North America and abroad.
A major recent milestone was the completed acquisition of POINT by Eli Lilly in December 2023, which effectively ended POINT’s life as an independent public company. That transaction is important in two ways: it validated the strategic value of POINT’s radiopharmaceutical platform, and it illustrates how premium oncology assets can become acquisition targets for larger pharma groups seeking radioligand capabilities. Prior to the acquisition, POINT reported positive topline results from the Phase 3 SPLASH trial of ^177Lu-PNT2002 in metastatic castration-resistant prostate cancer, a key clinical de-risking event for the lead program.
For investors in France, Belgium, and Switzerland, POINT Biopharma is a useful case study of a U.S.-based specialty biotech that built value through a narrow but differentiated oncology franchise. It was a United States company listed on NASDAQ, and its story was defined by targeted innovation, clinical progress, and eventual strategic absorption by a larger pharmaceutical platform.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
